94 Real-world use of sacubitril-valsartan in the south of England

94 Real-world use of sacubitril-valsartan in the south of England

BackgroundThe landmark PARADIGM-HF trial discovered that use of the angiotensin-receptor-neprolysin inhibitor sacubitril-valsartan (Sac-Val) led to significant reductions in mortality and heart failure hospitalisation. The inclusion criteria specified adults on a stable dose of angiotensin convertin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart (British Cardiac Society) 2020-07, Vol.106 (Suppl 2), p.A72-A73
Hauptverfasser: Dimarco, Anthony, Haydock, Paul, Flett, Andrew, Cowburn, Peter, Chandrasekaran, Badrinathan, Foley, Paul, Dixon, Giles, Jackson, Thomas, Critoph, Chris, Davis, Hannah, Kelly, Dominic
Format: Artikel
Sprache:eng
Schlagworte:
Blood pressure
Creatinine
Diabetes
Ejection fraction
Health risk assessment
Heart failure
Hypertension
Hypotension
Patients
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BackgroundThe landmark PARADIGM-HF trial discovered that use of the angiotensin-receptor-neprolysin inhibitor sacubitril-valsartan (Sac-Val) led to significant reductions in mortality and heart failure hospitalisation. The inclusion criteria specified adults on a stable dose of angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB) with NHYA class II-IV heart failure, left ventricular ejection fraction (LVEF)
ISSN:1355-6037
1468-201X
DOI:10.1136/heartjnl-2020-BCS.94